. "Erratum: Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial." Journal of Clinical Oncology, 2025. doi:10.1200/jco-24-02458